|
Press Releases |
|
 |
|
Tuesday, March 15, 2022 |
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
Friday, March 11, 2022 |
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
Wednesday, March 9, 2022 |
|
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) |
Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
Monday, March 7, 2022 |
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、自社創製のチロシンキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)の抗PD-1抗体「キイトルーダ(R)」(一般名:ペムブロリズマブ)との併用療法による治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得したことをお知らせします。 more info >> |
|
Friday, March 4, 2022 |
|
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク (Nasdaq: BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:ミシェル・ヴォナッソス、以下 バイオジェン)は、このたび、エーザイが、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブ(開発品コード:BAN2401)について、日本において医薬品事前評価相談制度に基づき、独立行政法人医薬品医療機器総合機構(PMDA)に申請データの提出を開始したことをお知らせします。 more info >> |
|
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). more info >> |
|
Friday, February 25, 2022 |
|
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma |
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
Friday, February 4, 2022 |
|
エーザイ、人事異動を発表 |
エーザイはこのたび、人事異動(2022年2月3日付 執行役人事異動)を以下のとおり発表しました。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 5세대 신호 릴레이용 차세대 접점 ‘극소형 크로스바 접점’ 개발
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES開發出適用於第5代訊號繼電器的次世代接點「極小CROSS BAR接點(帶狀接點)」
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES已开发了面向第5代信号继电器的次世代接点 “微小CROSS BAR接点(异型材带状接点)”
Mar 12, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops Miniaturized Micro Profile, a Next-Generation Contact tape for Fifth-Generation Signal Relays
Mar 12, 2025 11:00 JST
|
|
|
JCB Now Available on Google Play in Thailand, Indonesia, Vietnam, Philippines, and Hong Kong
Mar 12, 2025 11:00 JST
|
|
|
Bear Robotics「Carti 100」榮獲 2025 年 iF 設計大獎,引領物流自動化新標準
Mar 11, 2025 23:58 HKT/SGT
|
|
|
Bear Robotics' Carti 100 Wins iF DESIGN AWARD 2025, Setting New Standards in Logistics Automation
Mar 11, 2025 23:58 HKT/SGT
|
|
|
Formerra Introduces Formerra+ Upgraded Ecommerce Site to Optimize Customer Experience
Mar 11, 2025 22:15 HKT/SGT
|
|
|
135 Years of Sport Inspiration: U.S. Polo Assn. Hosts Celebration Cup Exhibition and Spring-Summer 2025 Fashion Showcase in Delhi
Mar 11, 2025 20:00 HKT/SGT
|
|
|
聯想控股旗下君聯資本、正奇能科集團共同投資企業漢朔科技在深交所成功上市
Mar 11, 2025 19:00 HKT/SGT
|
|
|
联想控股旗下君联资本、正奇能科集团共同投资企业汉朔科技在深交所成功上市
Mar 11, 2025 18:52 HKT/SGT
|
|
|
2024 Results of Qunabox Group Released: Leading AI Interactive Marketing with Strong Revenue and Profit Growth
Mar 11, 2025 18:50: JST
|
|
|
2024 Results of Qunabox Group Released: Leading AI Interactive Marketing with Strong Revenue and Profit Growth
Mar 11, 2025 17:50 HKT/SGT
|
|
|
JCB Announced Premier Sponsorship for the 10th Edition of Sakura 2025 at Singapore's Gardens by the Bay
Mar 11, 2025 18:00 JST
|
|
|
Hitachi Energy invests additional $250 million USD to address global transformer shortage
Mar 11, 2025 17:49 JST
|
|
|
|
More News >> |
|
|
|
|
|